

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FIL	ING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/637,529	08/11/2000		Robert C. Beck	1480 8331	
7	590	11/27/2006		EXAMINER	
ROBERT C. BECK				DESANTO, MATTHEW F	
BECK & TYSVER 2900 THOMAS AVE S #100			•	ART UNIT	PAPER NUMBER
MINNEAPOLIS, MN 55416-4463				3763	

DATE MAILED: 11/27/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	09/637,529	BECK, ROBERT C.				
Office Action Summary	Examiner	Art Unit				
	Matthew F. DeSanto	3763				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be timulated the control of t	l. ely filed the mailing date of this communication. (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 11 Second 2a) This action is FINAL. 2b) This 3) Since this application is in condition for allowant closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro					
Disposition of Claims						
4) Claim(s) 19 and 21-26 is/are pending in the appear 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) 19 and 21-26 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or Application Papers	vn from consideration.					
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the construction of the construct	epted or b) objected to by the Edrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa	te				

DETAILED ACTION

Claim Rejections - 35 USC § 102

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- 2. Claims and 19, 21-23, 25 are rejected under 35 U.S.C. 102(e) as being anticipated by Drasler et al. (USPN 5,496,267).

Drasler et al. discloses a fluid supply catheter, a lumen, a distal aperture (460), and a sheath (448), wherein said aperture defining a first aperture defining a first aperture direction for the emerging flow that lies between approximate zero degrees and ninety degrees and a control body (452) has an outer surface that is used to mix high pressure fluid with embolic material (Figure 44 and Column 11, lines 13-64)

3. Claim 26 are rejected under 35 U.S.C. 102(e) as being anticipated by Ruggio (USPN 5.476.450).

Ruggio discloses a fluid supply catheter, a lumen, a distal aperture (424), a control body (430) and a sheath, wherein the ablation catheter is located within the sheath and adapted for motion with respect to the sheath and wherein said aperture

Art Unit: 3763

defining a first aperture defining a first aperture direction for the emerging flow that lies between approximate zero degrees and ninety degrees. (Figures 12, 13, 14, 15 and entire reference)

Claim Rejections - 35 USC § 103

- 4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 5. Claim 24 is rejected under 35 U.S.C. 103(a) as being unpatentable over Drasler et al. (USPN 5,496,267) and further in view of Ruggio (USPN 5,476,450).

Drasler et al. discloses the claimed invention, but fails to disclose the distal end of the catheter is located within the sheath lumen.

Ruggio discloses the use of a delivery sheath and a therapeutic catheter for administering treatment to the patient (see figures 12-15).

Therefore, at the time of the invention it would have been obvious for one of ordinary skill in the art to combine the teachings of Drasler with Ruggio because Ruggio teaches the use of a guide catheter to be used since this allows for easier navigation then using several smaller tubes (Column 10 and 11). The examiner would also like to note that this modification would only take routine skill in the art since it is well known to use guide catheters to place a medical device in the body and that modifying the catheter to be able to move within a sheath is well known in the medical art, especially

Art Unit: 3763

when the medical device has a distal end that can penetrate or pierce a vessel wall.

Thus causing the medical device to be delivery through a tube.

Double Patenting

6. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

7. Claims 19, 21-26 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-16 of U.S. Patent No. 6,129,698. Although the conflicting claims are not identical, they are not patentably distinct from each other because the USPN 6129698 teaches a catheter body, apertures, and a control body and how the fluid interacts with the control body (see claim 1).

Response to Arguments

Applicant's arguments filed 9/11/06 have been fully considered, but are not persuasive. The examiner however has withdrawn the original rejection of Drasler with regards to figure 14 and has changed his rejection to figure 44, which reads on all the

claims of this application. Therefore the pervious 102 Rejection in view of Drasler has been withdrawn and the 103 of Kensey (USPN 4,631,052) and further in view of Ruggio (USPN 5,476,450).has also been withdrawn.

The examiner would also like to note that the remarks stated that claim 26 had been amended, but the claim 26 that was examined was the same claim 26 as previously presented. Therefore, the arguments drawn to the added limitations were disregarded.

Conclusion

8. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Matthew F. DeSanto whose telephone number is 571-272-4957. The examiner can normally be reached on Monday-Friday 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Nick LUCCHESI can be reached on (571) 272-4977. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Matthew DeSanto Art Unit 3763

November 21, 2006